Full-Time

Quality Assurance Supervisor

Swing Shift

Updated on 9/9/2026

Orca Bio

Orca Bio

201-500 employees

Develops and commercializes safer cell therapies

Compensation Overview

$80k - $110k/yr

+ Pre-IPO equity + Annual bonus

Sacramento, CA, USA

In Person

May work at either Sacramento facility; scheduled overtime, weekends, or holidays may be required.

Bachelor's

Category
Biology & Biotech (1)
Required Skills
GMP
Quality Assurance (QA)

Get referred to Orca Bio

See people who can refer or advise you

Requirements
  • Bachelor's degree in Life Sciences, Chemistry, Biology, or a related scientific discipline.
  • At least 5 years of Quality Assurance experience in a regulated pharmaceutical, biotechnology, or medical device environment.
  • Strong knowledge of current Good Manufacturing Practices, FDA, and International Council for Harmonisation guidelines.
  • Strong analytical, problem-solving, and decision-making skills.
  • Excellent written and verbal communication skills.
  • Strong organizational skills and attention to detail.
  • Ability to manage multiple priorities in a fast-paced environment.
  • Ability to meet cleanroom gowning requirements and wear full gowning for extended periods as needed.
  • Ability to work at either Orca Bio Sacramento location based on operational needs.
  • Ability to participate in video-based meetings and work scheduled overtime, weekends, or holidays based on business needs.
Responsibilities
  • Supervise, mentor, and develop QA technicians assigned to manufacturing and quality control operations.
  • Schedule and prioritize daily Quality Assurance activities to support production and laboratory functions.
  • Provide ongoing training, performance evaluations, and career development support for team members.
  • Represent Quality Assurance in cross-functional operations and quality-systems meetings.
  • Provide technical guidance and mentorship to ensure compliant, high-quality practices.
  • Oversee on-the-floor Quality Assurance support for manufacturing and quality control activities, including batch-record review, in-process checks, line clearance, and deviation response.
  • Ensure timely review and approval of manufacturing and quality-control documentation, including batch records, logbooks, equipment-use records, and test data.
  • Support real-time issue resolution during production and testing, escalating concerns as needed.
  • Monitor compliance with current Good Manufacturing Practices, Good Documentation Practices, and internal standard operating procedures.
  • Assist with preparing and reviewing master batch records, standard operating procedures, and related documentation.
  • Ensure effective implementation and adherence to quality systems, including deviation management, corrective and preventive actions, change control, and investigations.
  • Review and approve deviations, investigations, and change controls related to manufacturing and quality control.
  • Participate in internal audits, regulatory inspections, and third-party audits.
  • Support quality-data trending and continuous-improvement initiatives.
  • Collaborate with Quality Control, Manufacturing, Manufacturing Science and Technology, and other cross-functional teams to resolve quality and technical issues.
  • Monitor record-management conditions and practices for compliance with current Good Manufacturing Practices and FDA and European Medicines Agency regulations.
  • Manage documentation, equipment logs, and records to support internal and external inspection readiness.
  • Lead preparation for audits and regulatory inspections, including document reviews and mock audits.
  • Identify opportunities to improve operations, workflow efficiency, and compliance practices.
  • Participate in revising and developing standard operating procedures and policies.
  • Liaise with Manufacturing, Quality Control, Validation, Engineering, and other departments to ensure Quality Assurance oversight and alignment.
  • Communicate quality expectations, regulatory changes, and quality-system updates to the team and relevant stakeholders.
  • Support implementation of new procedures, processes, and equipment from a Quality Assurance perspective.
  • Perform other duties as requested by the supervisor or manager to support Quality.
  • Stay current with industry regulations, standards, and best practices related to Quality Assurance.
Desired Qualifications
  • One to two years of experience in a leadership or supervisory role.

Orca Bio develops and commercializes cell therapies to improve outcomes for patients. It works by researching, developing, and producing therapies that use the body’s own cells to treat diseases, with products sold to healthcare providers who administer them to patients. The company aims to enhance the safety and effectiveness of cell therapies, making treatments more reliable for conditions that lack good options. Orca Bio differentiates itself through its focus on delivering safer, more effective therapies and by fostering a strong team culture with active stakeholder communication, including a regularly updated newsroom. Overall, its goal is to expand access to improved cell therapies and become a leading player in the cell therapy market.

Company Size

201-500

Company Stage

Series F

Total Funding

$542M

Headquarters

Menlo Park, California

Founded

2016

Get referred to Orca Bio

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval on June 30, 2026 validates Orca Bio's platform and pipeline.
  • The company raised $250 million in December 2025, funding launch and expansion.
  • Princeton capacity and Sacramento hiring support commercialization and faster nationwide patient delivery.

What critics are saying

  • TREGZI costs $428,000, forcing transplant centers and payers into tough coverage fights.
  • Complex donor-specific manufacturing can bottleneck supply, delaying launches beyond the planned 25 centers.
  • Any post-marketing safety signal or FDA CMC issue would cripple Orca Bio's only commercial product.

What makes Orca Bio unique

  • Orca Bio's TREGZI won FDA approval on June 30, 2026, first precision cell therapy.
  • Its donor-derived regulatory T-cell design directly reduces chronic GVHD after transplant.
  • Princeton and Sacramento manufacturing create a bicoastal vein-to-vein network for personalized production.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Unlimited Paid Time Off

401(k) Retirement Plan

Parental Leave

Growth & Insights and Company News

Headcount

6 month growth

-1%

1 year growth

2%

2 year growth

-3%
Associated Press
Jul 1st, 2026
FDA approves Tregzi, first donor immune cell therapy cutting serious transplant complications in blood cancer patients by 70%

The US Food and Drug Administration has approved Tregzi, the first regulatory T cell-based immunotherapy for improving chronic graft-versus-host disease-free survival in adult blood cancer patients undergoing stem cell transplantation. The treatment uses donor-derived immune cells to help fight cancer whilst reducing the risk of chronic GVHD, a serious complication where transplanted donor cells attack the patient's body. In the PRECISION-T trial involving 187 patients, 78% of those receiving Tregzi achieved chronic GVHD-free survival at one year, compared to 38.4% receiving standard transplants. Only 12.6% of Tregzi patients developed serious chronic GVHD within one year versus 44% in the control group. The treatment, developed by Orca Biosystems, received Orphan Drug and Regenerative Medicine Advanced Therapy designations.

Fierce Pharma
Jul 1st, 2026
Orca Bio secures FDA approval for $428K cell therapy Tregzi, eyes potential IPO

Orca Bio has secured FDA approval for Tregzi, a first-of-its-kind engineered cell therapy for blood cancer patients requiring transplants. The allogeneic regulatory T cell-based immunotherapy is approved as an alternative stem cell transplant to improve survival free of chronic graft-versus-host disease in adults with hematological malignancies. In the phase 3 Precision-T trial involving 187 patients, 78% who received Tregzi were alive and free from chronic GVHD at one year, compared to 38% with standard transplants—a 74% improvement. Overall survival was 94% versus 83%. Orca is pricing Tregzi at $428,000 wholesale acquisition cost. The company recently raised $250 million and is launching at select centres, aiming for 25 by year-end. CEO Nate Fernhoff said the company is "well capitalised" for launch but didn't rule out a future IPO.

Associated Press
Jun 30th, 2026
Orca Bio's TREGZI becomes first FDA-approved precision cell therapy for blood cancer transplants

Orca Bio has received US FDA approval for TREGZI, the first precision-engineered cell therapy for matched-donor hematopoietic stem cell transplantation in adults with hematological malignancies. The therapy uses donor cells to reconstitute the immune system whilst suppressing graft-versus-host disease (GVHD). The approval is based on the Phase 3 Precision-T study of 187 patients with acute myeloid leukaemia, acute lymphoblastic leukaemia, myelodysplastic syndrome and mixed-phenotype acute leukaemia. Results showed 78% chronic GVHD-free survival at 12 months with TREGZI compared to 38% with conventional transplant. Overall survival was 94% versus 83%, whilst non-relapse mortality was 3% compared to 13%. TREGZI is a personalised treatment manufactured for each patient using living cells from a matched donor.

San Francisco Biotechnology Network
Jun 15th, 2026
Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval.

Orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. June 15, 2026 san francisco biotechnology network news news, syndication comments off on orca Bio expands Sacramento workforce, adds East Coast manufacturing site ahead of approval. Orca Bio, a biotechnology company that works in precision cell therapy, has expanded its Sacramento workforce and added an East Coast manufacturing center in Princeton, New Jersey, as it prepares for commercialization. Click here to view original post

Business Wire
Jun 15th, 2026
Orca Bio expands manufacturing for Orca-T launch with East Coast facility and tripled workforce

Orca Bio has expanded its manufacturing capabilities ahead of the potential launch of its lead cell therapy, Orca-T, adding East Coast manufacturing capacity in Princeton, New Jersey, and tripling its West Coast manufacturing workforce in Sacramento, California. The Princeton facility will serve as a strategic East Coast manufacturing bridge, initially producing therapies for ongoing clinical programmes and supporting commercial production following potential FDA approval. The bicoastal network aims to reduce "vein-to-vein" time for patients nationwide. Orca Bio has more than tripled its Sacramento operations team over the past year, enhancing expertise in manufacturing, supply chain logistics and quality assurance. Orca-T's Biologics License Application is under FDA review, with a target action date of 6 July 2026.